Study guide
This chapter combines neuroanatomy/neurophysiology, neuropathology and special senses, psychiatric/behavioral science mechanisms, human development across the lifespan, and biostatistics/epidemiology — a broad but consistently tested cross-section of the exam. Biostatistics and epidemiology, in particular, appear throughout Step 1 as calculation-based items (risk measures, test characteristics, study design) rather than confined to one block, so quantitative fluency here pays off across the whole exam. Neuroanatomic pathway tracing and psychopharmacologic mechanism questions reward the same systematic, mechanism-first approach used in the other organ systems.
Ascending Sensory Pathways
The two major ascending sensory pathways differ in modality, decussation site, and clinical lesion patterns, making pathway-tracing questions some of the most reliably testable neuroanatomy on Step 1. The dorsal column-medial lemniscus pathway carries vibration, proprioception, and fine touch: first-order neurons enter the spinal cord and ascend ipsilaterally in the dorsal columns without synapsing at the level of entry, synapse in the gracile or cuneate nucleus of the caudal medulla, and only then do second-order neurons decussate as internal arcuate fibers to ascend contralaterally as the medial lemniscus toward the thalamus (VPL nucleus) and ultimately the primary somatosensory cortex. The anterolateral (spinothalamic) pathway carries pain and temperature: first-order neurons synapse immediately in the dorsal horn, and second-order neurons decussate at that same spinal level via the anterior (ventral) white commissure before ascending contralaterally. This difference in decussation level explains classic lesion patterns: a hemicord lesion (Brown-Sequard syndrome) causes ipsilateral loss of vibration/proprioception but contralateral loss of pain/temperature below the lesion, because the two pathways have already crossed at different levels. Always identify which modality is described in a vignette before deciding where decussation occurs — this is the single most common source of error on these questions.
Special Senses: Cochlear Tonotopy and Hearing Loss
The cochlea is tonotopically organized along the length of the basilar membrane, and this organization explains why patterns of hearing loss localize to specific cochlear regions. The base of the cochlea (nearest the oval/round windows) has a narrow, stiff basilar membrane that resonates preferentially to high-frequency sound, while the apex has a wide, compliant membrane tuned to low frequencies; because high-frequency-responsive hair cells at the base are more mechanically stressed and more vulnerable to noise trauma, ototoxic drugs (aminoglycosides, loop diuretics, cisplatin), and age-related degeneration, high-frequency sensorineural hearing loss (as in presbycusis or chronic noise exposure) is typically the earliest and most pronounced deficit. Sensorineural hearing loss (cochlear or CN VIII pathology) is distinguished from conductive hearing loss (external/middle ear pathology) using the Weber and Rinne tests: in sensorineural loss, Weber lateralizes to the unaffected (better-hearing) ear and Rinne shows air conduction greater than bone conduction bilaterally (normal pattern) but reduced overall on the affected side; in conductive loss, Weber lateralizes to the affected ear and Rinne shows bone conduction greater than air conduction on that side. This physiology-to-bedside-test mapping is a recurring integrative theme across special senses content.
Dopamine Pathways and Antipsychotic Pharmacology
Four major dopaminergic pathways in the brain have distinct functions, and antipsychotic drugs' therapeutic and adverse effect profiles are best understood by mapping D2-receptor blockade onto each pathway. The mesolimbic pathway mediates reward and is hyperactive in psychosis, so dopamine hyperactivity here drives positive symptoms (hallucinations, delusions), which improve with D2 antagonism — the therapeutic target of antipsychotics. The mesocortical pathway's relative hypofunction is instead linked to negative symptoms (flat affect, avolition) and cognitive symptoms, which are not improved (and may be worsened) by D2 blockade, explaining why first-generation antipsychotics are less effective for negative symptoms. The nigrostriatal pathway regulates voluntary movement; blocking dopamine here produces extrapyramidal side effects (acute dystonia, akathisia, parkinsonism, and with chronic blockade, tardive dyskinesia). The tuberoinfundibular pathway tonically inhibits prolactin release from the anterior pituitary; D2 blockade here removes this inhibition, causing hyperprolactinemia (galactorrhea, amenorrhea, sexual dysfunction). Second-generation (atypical) antipsychotics have relatively more serotonin (5-HT2A) antagonism relative to D2 blockade, which reduces extrapyramidal and prolactin side effects while treating both positive and, to some degree, negative symptoms.
GABA Pharmacology: Benzodiazepines and Barbiturates
Both benzodiazepines and barbiturates potentiate inhibitory GABA-A receptor signaling, but through mechanistically distinct allosteric actions that produce different safety profiles, a frequently tested contrast. Benzodiazepines are positive allosteric modulators that increase the frequency of GABA-gated chloride channel opening, but only in the presence of GABA — meaning their effect has a ceiling and, critically, pure benzodiazepine overdose alone rarely causes fatal respiratory depression, and flumazenil (a competitive GABA-A receptor antagonist) can reverse toxicity. Barbiturates instead increase the duration of channel opening and, at high concentrations, can directly open the chloride channel independent of GABA binding, which removes any therapeutic ceiling and makes barbiturate overdose far more dangerous, particularly through respiratory and cardiovascular depression, with no specific reversal agent. This mechanistic distinction (frequency vs. duration of channel opening, and GABA-dependence vs. GABA-independence at high dose) also explains why benzodiazepines are preferred for anxiety and alcohol withdrawal management despite barbiturates sharing the same receptor target. Clinically, benzodiazepines are additionally used for seizures, procedural sedation, and muscle relaxation, while barbiturates are largely reserved for refractory status epilepticus and anesthesia induction given their narrower safety margin.
Biostatistics: Study Design and Diagnostic/Therapeutic Measures
Biostatistics questions typically require applying a formula correctly to a described scenario rather than reciting a definition, so practice with numeric application matters as much as conceptual understanding. From a randomized controlled trial reporting event rates in treatment and control arms, absolute risk reduction (ARR) is the arithmetic difference between control and treatment event rates, and number needed to treat (NNT) is its reciprocal (1/ARR), rounded up to the next whole patient since NNT must represent a whole number of people treated to prevent one additional event; relative risk reduction, by contrast, is ARR divided by the control event rate and is often used (sometimes misleadingly) to make an effect appear larger than the absolute numbers support. Diagnostic test characteristics (sensitivity, specificity, positive and negative predictive value, likelihood ratios) depend on disease prevalence for predictive values but not for sensitivity/specificity, a distinction commonly tested by varying prevalence across otherwise identical stems. Study design concepts — cohort studies (calculate relative risk, can assess incidence, appropriate for common exposures/rare-to-common outcomes), case-control studies (calculate odds ratio, efficient for rare diseases, prone to recall bias), and cross-sectional studies (assess prevalence at a single time point) — are tested by matching design features and susceptible biases (selection bias, recall bias, lead-time bias, confounding) to a described study scenario. Always identify what is being calculated (risk in exposed/unexposed, or odds) before selecting a formula.
Key terms
- Dorsal column-medial lemniscus pathway
- — Ascending pathway for vibration, proprioception, and fine touch that decussates late, in the caudal medulla, as internal arcuate fibers.
- Anterolateral (spinothalamic) pathway
- — Ascending pathway for pain and temperature that decussates early, at the spinal level of entry, via the anterior white commissure.
- Cochlear tonotopy
- — The frequency-mapped organization of the basilar membrane, with the stiff base tuned to high frequencies and the compliant apex tuned to low frequencies.
- Mesolimbic pathway
- — The dopaminergic pathway whose hyperactivity produces the positive symptoms of psychosis and is the therapeutic target of D2-blocking antipsychotics.
- Tuberoinfundibular pathway
- — The dopaminergic pathway that tonically inhibits prolactin; its blockade by antipsychotics causes hyperprolactinemia.
- Number needed to treat (NNT)
- — The reciprocal of the absolute risk reduction (1/ARR), representing the number of patients who must be treated to prevent one additional adverse outcome.
- Thelarche
- — Breast budding, typically the first observable sign of puberty in girls, preceding pubarche, peak height velocity, and menarche.
- Flumazenil
- — A competitive GABA-A receptor antagonist used to reverse benzodiazepine (but not barbiturate) toxicity.
Exam tips
- Before answering a decussation question, first identify the modality in the stem (vibration/proprioception vs. pain/temperature) — that alone tells you whether to expect late medullary or immediate spinal-level crossing.
- High-frequency hearing loss localizes to the cochlear base, not the apex; use this to answer both noise-induced hearing loss and aminoglycoside-ototoxicity vignettes.
- Match each antipsychotic side effect to its pathway: extrapyramidal symptoms/tardive dyskinesia to nigrostriatal blockade, hyperprolactinemia to tuberoinfundibular blockade, and treatment of positive symptoms to mesolimbic blockade.
- On NNT/ARR questions, compute ARR first (control rate minus treatment rate), then take the reciprocal and round up — do not round down, since NNT must reflect whole patients.
- Remember only barbiturates (not benzodiazepines) can directly open the chloride channel independent of GABA at high dose — this is the mechanistic reason barbiturate overdose is more dangerous and lacks a reliable antidote.
- For pubertal timing questions in girls, memorize the sequence thelarche then pubarche then peak growth velocity then menarche; boys' sequence (testicular enlargement first) is a common confusable pair on the same question type.